Simplex Trading, LLC Surface Oncology, Inc. Transaction History

Simplex Trading, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	SELL	$0.57 - $0.88 $4,051 - $6,255	-7,108 Reduced 25.9%	20,332 $17,000
Q1 2023 Apr 27, 2023	BUY	$0.61 - $1.03 $14,349 - $24,229	23,524 Added 600.72%	27,440 $19,000
Q4 2022 Feb 02, 2023	SELL	$0.62 - $1.21 $9 - $18	-15 Reduced 0.38%	3,916 $3,000
Q3 2022 Nov 04, 2022	BUY	$1.05 - $2.1 $4,127 - $8,255	3,931 New	3,931 $4,000
Q2 2022 Aug 03, 2022	SELL	$1.42 - $3.15 $3,517 - $7,802	-2,477 Closed	0 $0
Q1 2022 May 02, 2022	SELL	$2.65 - $5.08 $4,006 - $7,680	-1,512 Reduced 37.9%	2,477 $7,000
Q4 2021 Feb 23, 2022	SELL	$4.73 - $7.9 $19,454 - $32,492	-4,113 Reduced 50.77%	3,989 $19,000
Q3 2021 Oct 28, 2021	SELL	$5.16 - $7.98 $1,032 - $1,596	-200 Reduced 2.41%	8,102 $59,000
Q2 2021 Aug 12, 2021	SELL	$6.45 - $9.09 $44,969 - $63,375	-6,972 Reduced 45.65%	8,302 $61,000
Q1 2021 Apr 26, 2021	SELL	$7.25 - $13.82 $4,545 - $8,665	-627 Reduced 3.94%	15,274 $119,000
Q4 2020 Feb 02, 2021	BUY	$6.87 - $10.48 $73,811 - $112,597	10,744 Added 208.34%	15,901 $0
Q3 2020 Oct 14, 2020	BUY	$5.06 - $7.23 $26,094 - $37,285	5,157 New	5,157 $0

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.